EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Improvements in Patient-Reported Outcome Measures Through 64 Weeks’ Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension

Richard B Lipton, Dawn C Buse, Vincent T Martin, Dave Semel, Joseph C Cappelleri iD, Alexandra Thiry, Lucy Abraham, Terence Fullerton

Journal of Pain Research · 2026-09 · Volume 19 · 1-13

DOI: 10.2147/jpr.s612330 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pain Research, 2026-09. Verfasst von Richard B Lipton und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The current exploratory analysis of a Phase 2/3 randomized controlled trial focusses on patient-reported outcome measures from a 64-week study evaluating rimegepant for the preventive treatment of migraine in the USA.

Methods

Participants with migraine were randomly assigned to rimegepant 75 mg or placebo every other day during a 12-week double-blind treatment (DBT) phase. During a 52-week open-label extension (OLE) phase all participants took rimegepant 75 mg every other day and additionally on nonscheduled dosing days if needed. Migraine-Specific Quality of Life Questionnaire (MSQ) v.2.1 (including Role Function Restrictive [RFR] domain) and Migraine Disability Assessment Scale (MIDAS) were assessed throughout.

Results

741 participants (mean [standard deviation] age 41.2 [13.06] years, 82.7% female) were treated with ≥1 dose of study drug in the DBT phase, and 603 participants were treated with rimegepant in the OLE phase. At Week 12 (end of DBT phase), for the rimegepant and placebo groups, respectively, mean (95% CI) improvements from baseline in MSQ RFR score were 18.6 (16.24, 20.94) and 15.0 (12.60, 17.37), and improvements in MIDAS Total score were -13.0 (-16.57, -9.52) and -12.0 (-15.52, -8.54). At Week 64 (end of OLE phase, all participants taking open-label rimegepant), for participants originally assigned DBT rimegepant and DBT placebo, respectively, mean (95% CI) improvements from baseline in MSQ RFR score were 32.6 (29.68, 35.42) and 33.2 (30.03, 36.29), and improvements from baseline in MIDAS Total Score were -25.4 (-30.23, -20.48) and -24.4 (-28.29, -20.59).

Conclusion

Notable numerical benefit for rimegepant versus placebo was observed at the end of the DBT phase (Week 12) for MSQ RFR domain score. During open-label treatment with rimegepant, improvements from baseline in MSQ domain scores and MIDAS Total Score were clinically meaningful at Week 64. Participants who received placebo in the DBT phase achieved similar benefit when they moved into the OLE phase as those who took rimegepant from the start of the study. Trial Registration: Clinicaltrials.gov NCT03732638. Migraine affects every part of daily life, including home, work, education, and relationships. Quality of life is decreased, and more frequent migraine attacks cause greater migraine-related disability. Patient-reported results are important in clinical trials of treatments for migraine. This report looked at the patient-reported results from a 64-week study assessing rimegepant for the preventive treatment of migraine. Participants with migraine took rimegepant or placebo (a dummy pill) every other day for 12 weeks, then everyone could take rimegepant up to once each day for the next 52 weeks. During the study, the participants completed questionnaires including the Migraine-Specific Quality of Life Questionnaire (MSQ) and the Migraine Disability Assessment Scale (MIDAS). When researchers looked at the MSQ results at Week 12, participants generally had better scores compared with before treatment, but the improvement seemed bigger for those taking rimegepant than those taking placebo. The researchers found that treatment with rimegepant for up to 64 weeks was linked to improvements in MSQ and MIDAS results compared with before treatment. This means the study participants reported their quality of life and migraine-related disability improved when they took rimegepant for the preventive treatment of migraine for up to 64 weeks.

Schlagwörter

Stichwörter der Autor:innen

calcitonin gene-related peptide receptor antagonistdisabilitymigrainequality of life

Autor:innen und Institutionen

  • Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Headache and Facial Pain Center, University of Cincinnati, Cincinnati, OH, USA.
  • Medical Affairs, Pfizer Inc, New York, NY, USA.
  • Department of Statistics, Pfizer Inc, Groton, CT, USA.
  • Health Economics & Outcomes Research, Pfizer R&D UK Ltd, Tadworth, UK.

ORCID-Profile: Joseph C Cappelleri

Zitieren

APA

Lipton, R. B., Buse, D. C., Martin, V. T., Semel, D., Cappelleri, J. C., Thiry, A., Abraham, L., & Fullerton, T. (2026). Improvements in Patient-Reported Outcome Measures Through 64 Weeks’ Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension. Journal of Pain Research, Volume 19, 1-13. https://doi.org/10.2147/jpr.s612330

Vancouver

Lipton RB, Buse DC, Martin VT, Semel D, Cappelleri JC, Thiry A, et al. Improvements in Patient-Reported Outcome Measures Through 64 Weeks’ Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension. Journal of Pain Research. 2026;Volume 19:1-13. doi:10.2147/jpr.s612330

BibTeX
@article{Lipton2026,
  author = {Lipton, Richard B and Buse, Dawn C and Martin, Vincent T and Semel, Dave and Cappelleri, Joseph C and Thiry, Alexandra and Abraham, Lucy and Fullerton, Terence},
  title = {Improvements in Patient-Reported Outcome Measures Through 64 Weeks’ Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension},
  journal = {Journal of Pain Research},
  year = {2026},
  volume = {Volume 19},
  pages = {1--13},
  doi = {10.2147/jpr.s612330}
}
Kostenlos starten →